biote Corp. (NasdaqGM: BTMD)
Health Care · Pharmaceuticals · US
$1.58
+0.64% today · -52.3% 1Y
biote Corp. (NasdaqGM: BTMD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $45.31M and employs 223 people.
Over the last twelve months the share price has lost 52.3%, trading between 1.27 and 3.62.
Tweenvest scores biote Corp. across four factors: quality 60/100, value 44/100, growth 38/100. Its strongest factor is quality.
BTMD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $45.31M
- Revenue (TTM)
- $183.53M
- P/E
- 8.71
- EPS
- 0.18
- Dividend yield
- —
- Beta (5Y)
- 1.65
- 52-week high
- $3.62
- 52-week low
- $1.27
- Avg volume (3M)
- —
- Shares outstanding
- 28.68M
- Employees
- 223
- Next earnings
- —
About biote Corp.
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
- ISIN
- US0906831039
- Founded
- 2012
- Listed since
- Apr 28, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,235.35 | +0.14% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.38 | +0.09% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.17 | -0.18% |
| Roche Holding AGSWX: ROP | $371.62B | CHF374.20 | +0.11% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.68 | -0.87% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.51 | -0.21% |
Figures last refreshed Aug 18, 2026.